On September 17, 2024, Altamira Therapeutics Ltd. initiated a public offering of common shares and various series of warrants, with H.C. Wainwright & Co. serving as the exclusive placement agent. The offering included 377,000 common shares, pre-funded warrants to purchase over 5 million common shares, and two series of warrants (Series A-1 and Series A-2) each to purchase up to approximately 5.5 million common shares. The offering was priced at $0.72 per share and warrant, with pre-funded warrants priced at $0.718 each. The pre-funded warrants are exercisable immediately at $0.002 per share and expire upon full exercise. The Series A-1 and Series A-2 warrants are also immediately exercisable at $0.72 per share, with the former expiring 18 months post-issuance or 60 days after positive biodistribution data for...Show More

On September 17, 2024, Altamira Therapeutics Ltd. initiated a public offering of common shares and various series of warrants, with H.C. Wainwright & Co. serving as the exclusive placement agent. The offering included 377,000 common shares, pre-funded warrants to purchase over 5 million common shares, and two series of warrants (Series A-1 and Series A-2) each to purchase up to approximately 5.5 million common shares. The offering was priced at $0.72 per share and warrant, with pre-funded warrants priced at $0.718 each. The pre-funded warrants are exercisable immediately at $0.002 per share and expire upon full exercise. The Series A-1 and Series A-2 warrants are also immediately exercisable at $0.72 per share, with the former expiring 18 months post-issuance or 60 days after positive biodistribution data for AM-401 or AM-411 nanoparticles is announced, and the latter expiring five years post-issuance or six months after agreements for further development and commercialization of AM-401 or AM-411 are announced. The offering closed on September 19, 2024, with net proceeds of approximately $3.3 million, excluding potential proceeds from the exercise of the warrants, which could bring in an additional $8.0 million. The funds are intended for working capital and general corporate purposes. In conjunction with the offering, the company entered into a securities purchase agreement with an institutional investor and issued lock-up agreements with its directors and officers. Additionally, the company amended existing warrants to reduce the exercise price to $0.72 per share and extend the expiration to five years post-closing of the offering.